Please assess the completion status of the following clinical trial:

Trial Title: Human Beta-2 Adrenergic Stimulation and Muscle Glucose Uptake

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Caucasian;~2. Male sex;~3. Age: 18-30~4. BMI: 18-25 kg/m2;~5. Normal physical activity levels;~Exclusion Criteria:~1. Not meeting all inclusion criteria~2. Cardiovascular diseases (determined by means of questionnaires, heart rate/blood pressure measurements)~3. Respiratory diseases (including asthma, bronchitis and COPD);~4. Unstable body weight (weight gain or loss \> 5 kg in the last three months);~5. Intention to lose or gain body weight (e.g. with caloric restriction or physical activity)~6. Excessive alcohol and/or drug abuse;~7. Hypokalaemia;~8. Hb \< 8.4 mmol/L;~9. Epilepsy;~10. Smoking;~11. Renal and/or liver insufficiency;~12. Participation in another biomedical study within 1 month before the first study visit, possibly interfering with the study results;~13. Medication use known to hamper subject's safety during the study procedures;~14. Subjects who do not want to be informed about unexpected medical findings;~15. Subjects who do not want that their treating physician to be informed;~16. Inability to participate and/or complete the required measurements;~17. Participation in organised or structured physical exercise;~18. Any condition, disease or abnormal laboratory test result that, in the opinion of the Investigator, would interfere with the study outcome, affect trial participation or put the subject at undue risk;~19. Hyperthyroidism

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Clenbuterol hydrochloride (Type: EXPERIMENTAL): Subjects will ingest clenbuterol hydrochloride capsules (20 microgram/each) twice daily (40 microgram/day) for a maximum of 14 days.~Subjects that received the clenbuterol hydrochloride capsules (at random) in the first study period will receive the placebo capsules during the second study period.
- Placebos (Type: PLACEBO_COMPARATOR): Subjects will ingest placebo capsules matching the clenbuterol hydrochloride capsules one time per day for a maximum of 14 days.~Subjects that received the placebo capsules (at random) in the first study period will receive the clenbuterol hydrochloride capsules during the second study period.

Based on this trial design, predict the completion outcome and termination type (if applicable).